細胞および遺伝子治療の製造QC (品質管理)：欧州市場の分析・予測 (2023-2033年)

欧州の細胞および遺伝子治療の製造QC (品質管理) の市場規模は、2023年の5億3,430万米ドルから、予測期間は16.90%のCAGRで推移し、2033年には25億4,560万米ドルの規模に成長すると予測されています。

欧州の細胞および遺伝子治療の製造QC (品質管理) 市場：イントロダクション

欧州の細胞および遺伝子治療の製造QC (品質管理) 市場は、承認された治療法の増加とインフラ拡充の必要性から拡大が予測されています。さらに、細胞および遺伝子治療が対象とする疾患が広範囲に及ぶため、大規模な製造とQCプロセスが必要となり、市場成長に寄与しています。

欧州の細胞および遺伝子治療の製造QC市場は、いくつかの要因によって著しい成長を遂げています。さまざまな疾患の治療に細胞療法や遺伝子療法が採用されるようになるにつれ、これらの先進療法の安全性、有効性、一貫性を確保するための厳格な品質管理対策に対する需要が高まっています。欧州の規制機関は高い製造基準の維持を重視しており、市場の拡大をさらに後押ししています。さらに、分析技術や自動化の進歩もQCプロセスを強化し、効率的で信頼性の高い製造を促進しています。さらに、学術機関、バイオ医薬品企業、製造受託機関 (CMO) の連携が、革新的なQCソリューションの開発に貢献しています。欧州が細胞治療と遺伝子治療の分野で主導的な役割を果たし続ける中、QC市場は継続的な成長と革新の態勢を整えています。

当レポートでは、欧州の細胞および遺伝子治療の製造QC (品質管理) の市場を調査し、市場概要、市場成長への各種影響因子の分析、法規制環境、市場規模の推移・予測、各種区分・主要国別の詳細分析、主要企業の分析などをまとめています。

市場の分類

セグメンテーション1：治療タイプ別

• 細胞治療
• 遺伝子治療

セグメンテーション2：製品別

• 製品
• サービス

セグメンテーション3：プロセス別

• 原料調製
• 上流工程
• 下流工程
• 包装

セグメンテーション4：用途別

• 安全性試験
• 力価試験
• 同一性試験
• 安定性・遺伝的忠実性試験
• その他

セグメンテーション5：技術別

• ポリメラーゼ連鎖反応 (PCR)
• フローサイトメトリー
• リムルスアメーバサイトライセート (LAL)
• 酵素結合免疫吸着測定法 (ELISA)
• クロマトグラフィー
• 質量分析
• ウェスタンブロッティング
• 次世代シーケンス (NGS)
• 電気泳動
• その他の技術

セグメンテーション6：国別

• 英国
• ドイツ
• フランス
• イタリア
• スペイン
• その他

主な参入企業：

• bioMerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza.
• Sartorius AG

目次

エグゼクティブサマリー

第1章 市場

• 製品の定義
• 市場範囲
• 調査手法
• 市場概要
  • 世界市場のシナリオ
  • 市場のフットプリントと成長の可能性
  • 将来性
  • COVID-19による市場への影響

第2章 細胞および遺伝子治療の製造QC (品質管理) 市場：業界分析

• 規制の枠組み

第3章 欧州

• 概要
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• スペイン
• その他の地域
  • 提供区分別市場
  • 治療タイプ別市場
  • プロセス別市場
  • 技術別市場
  • 用途別市場

第4章 企業プロファイル

• 製造業者
• サービス

List of Figures

• Figure 1: Europe Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
• Figure 2: Europe Cell and Gene Therapy Manufacturing QC Market, Impact Analysis
• Figure 3: Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), % Share, 2022 and 2033
• Figure 4: Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), % Share, 2022 and 2033
• Figure 5: Europe Cell and Gene Therapy Manufacturing QC Market (by Process), % Share, 2022 and 2033
• Figure 6: Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), % Share, 2022 and 2033
• Figure 7: Europe Cell and Gene Therapy Manufacturing QC Market (by Application), % Share, 2022 and 2033
• Figure 8: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
• Figure 9: Cell and Gene Therapy Manufacturing QC Market: Research Methodology
• Figure 10: Primary Research Methodology
• Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 12: Top-Down Approach (Segment-Wise Analysis)
• Figure 13: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2033
• Figure 14: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022-2033
• Figure 15: Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022-2033
• Figure 16: Europe Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
• Figure 17: Impact of COVID-19 on CGT Developmental Activities
• Figure 18: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
• Figure 19: Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
• Figure 20: Europe Cell and Gene Therapy Manufacturing QC Market (by Country), % Share, 2022-2033
• Figure 21: Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
• Figure 22: Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
• Figure 23: Europe Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
• Figure 24: Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
• Figure 25: Europe Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
• Figure 26: U.K. Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
• Figure 27: U.K. Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
• Figure 28: U.K. Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
• Figure 29: U.K. Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
• Figure 30: U.K. Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
• Figure 31: U.K. Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
• Figure 32: Germany Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
• Figure 33: Germany Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
• Figure 34: Germany Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
• Figure 35: Germany Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
• Figure 36: Germany Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
• Figure 37: Germany Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
• Figure 38: France Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
• Figure 39: France Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
• Figure 40: France Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
• Figure 41: France Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
• Figure 42: France Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
• Figure 43: France Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
• Figure 44: Italy Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
• Figure 45: Italy Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
• Figure 46: Italy Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
• Figure 47: Italy Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
• Figure 48: Italy Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
• Figure 49: Italy Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
• Figure 50: Spain Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
• Figure 51: Spain Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
• Figure 52: Spain Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
• Figure 53: Spain Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
• Figure 54: Spain Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
• Figure 55: Spain Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
• Figure 56: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
• Figure 57: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
• Figure 58: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
• Figure 59: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
• Figure 60: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
• Figure 61: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
• Figure 62: Total Number of Companies Profiled
• Figure 63: bioMerieux SA: Product Portfolio
• Figure 64: bioMerieux SA: Overall Financials, $Million, 2020-2022
• Figure 65: bioMerieux SA: Revenue (by Segment), $Million, 2020-2022
• Figure 66: bioMerieux SA: Revenue (by Region), $Million, 2020-2022
• Figure 67: F. Hoffmann-La Roche Ltd: Product Portfolio
• Figure 68: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
• Figure 69: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
• Figure 70: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2020-2022
• Figure 71: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
• Figure 72: Lonza.: Product Portfolio
• Figure 73: Lonza.: Overall Financials, $Million, 2020-2022
• Figure 74: Lonza.: Revenue (by Segment), $Million, 2021and 2022
• Figure 75: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
• Figure 76: Sartorius AG: Product Portfolio
• Figure 77: Sartorius AG: Overall Financials, $Million, 2020-2022
• Figure 78: Sartorius AG: Revenue (by Segment), $Million, 2020-2022
• Figure 79: Sartorius AG: Revenue (by Region), $Million, 2020-2022
• Figure 80: Eurofins Scientific: Product Portfolio
• Figure 81: Eurofins Scientific.: Overall Financials, $Million, 2020-2022
• Figure 82: Eurofins Scientific.: Revenue (by Segment), $Million, 2020-2022
• Figure 83: Eurofins Scientific.: Revenue (by Region), $Million, 2020-2022
• Figure 84: Merck KGaA: Product Portfolio
• Figure 85: Merck KGaA: Overall Financials, $Million, 2020-2022
• Figure 86: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
• Figure 87: Merck KGaA: Revenue (by Region), $Million, 2020-2022

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
• Table 3: Europe Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis

The Europe Cell and Gene Therapy Manufacturing QC Market Expected to Reach $2,545.6 Million by 2033

Introduction to Europe Cell and Gene Therapy Manufacturing QC Market

The Europe cell and gene therapy manufacturing Quality Control (QC) market is expected to reach $2,545.6 million by 2033 from $534.3 million in 2023 at a CAGR of 16.90% during the forecast period 2023-2033. The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The cell and gene therapy manufacturing Quality Control (QC) market in Europe is experiencing notable growth driven by several factors. With the increasing adoption of cell and gene therapies for treating various diseases, there's a rising demand for stringent quality control measures to ensure the safety, efficacy, and consistency of these advanced therapies. European regulatory bodies' emphasis on maintaining high manufacturing standards further propels market expansion. Additionally, advancements in analytical technologies and automation are enhancing QC processes, facilitating efficient and reliable manufacturing. Furthermore, collaborations between academic institutions, biopharmaceutical companies, and contract manufacturing organizations (CMOs) contribute to the development of innovative QC solutions. As Europe continues to play a leading role in the cell and gene therapy landscape, the QC market is poised for continued growth and innovation.

Market Segmentation

Segmentation 1: by Therapy Type

• Cell Therapy
• Gene Therapy

Segmentation 2: by Offering

• Products
• Services

Segmentation 3: by Process

• Raw Material Preparation
• Upstream Processing
• Downstream Processing
• Packaging

Segmentation 4: by Application

• Safety Testing
• Potency Testing
• Identity Testing
• Stability and Genetic Fidelity Testing
• Others

Segmentation 5: by Technology

• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Limulus Amebocyte Lysate (LAL)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Mass Spectrometry
• Western Blotting
• Next-Generation Sequencing (NGS)
• Electrophoresis
• Other Technologies

Segmentation 6: by Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current Europe cell and gene therapy manufacturing QC market.

Competitive Strategy: Key players in the Europe cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• bioMerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza.
• Sartorius AG

Table of Contents

Executive Summary

1 Markets

• 1.1 Product Definition
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
• 1.2 Market Scope
  • 1.2.1 Key Questions Answered in the Report
• 1.3 Research Methodology
  • 1.3.1 Cell and Gene Therapy Manufacturing QC Market
  • 1.3.2 Data Sources
    • 1.3.2.1 Primary Data Sources
    • 1.3.2.2 Secondary Data Sources
  • 1.3.3 Market Estimation Model
  • 1.3.4 Criteria for Company Profiling
• 1.4 Market Overview
  • 1.4.1 Global Market Scenario
    • 1.4.1.1 Realistic Growth Scenario
    • 1.4.1.2 Optimistic Scenario
    • 1.4.1.3 Pessimistic Scenario
  • 1.4.2 Market Footprint and Growth Potential
  • 1.4.3 Future Potential
  • 1.4.4 COVID-19 Impact on Market
    • 1.4.4.1 Impact on Research and Clinical Operations
    • 1.4.4.2 COVID-19 Impact: Current Scenario of the Market
    • 1.4.4.3 Pre- and Post-COVID-19 Impact Assessment
      • 1.4.4.3.1 Pre-COVID-19 Phase
      • 1.4.4.3.2 Post-COVID-19 Phase

2 Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

• 2.1 Regulatory Framework
  • 2.1.1 Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
    • 2.1.1.1 Product Testing
    • 2.1.1.2 Microbial Testing
    • 2.1.1.3 Identity
    • 2.1.1.4 Purity
    • 2.1.1.5 Potency
    • 2.1.1.6 Viability
    • 2.1.1.7 Cell Number or Dose
  • 2.1.2 Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
    • 2.1.2.1 Characterization
    • 2.1.2.2 Identity Testing
    • 2.1.2.3 Purity Testing
  • 2.1.3 Current Good Manufacturing Practice (CGMP) Regulations
    • 2.1.3.1 Europe
  • 2.1.4 Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3 Europe

• 3.1 Overview
• 3.2 Europe
  • 3.2.1 Europe Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.2.2 Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.2.3 Europe Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.2.4 Europe Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.2.5 Europe Cell and Gene Therapy Manufacturing QC Market (by Application)
• 3.3 U.K.
  • 3.3.1 U.K. Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.3.2 U.K. Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.3.3 U.K. Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.3.4 U.K. Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.3.5 U.K. Cell and Gene Therapy Manufacturing QC Market (by Application)
• 3.4 Germany
  • 3.4.1 Germany Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.4.2 Germany Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.4.3 Germany Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.4.4 Germany Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.4.5 Germany Cell and Gene Therapy Manufacturing QC Market (by Application)
• 3.5 France
  • 3.5.1 France Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.5.2 France Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.5.3 France Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.5.4 France Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.5.5 France Cell and Gene Therapy Manufacturing QC Market (by Application)
• 3.6 Italy
  • 3.6.1 Italy Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.6.2 Italy Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.6.3 Italy Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.6.4 Italy Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.6.5 Italy Cell and Gene Therapy Manufacturing QC Market (by Application)
• 3.7 Spain
  • 3.7.1 Spain Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.7.2 Spain Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.7.3 Spain Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.7.4 Spain Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.7.5 Spain Cell and Gene Therapy Manufacturing QC Market (by Application)
• 3.8 Rest-of-Europe
  • 3.8.1 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.8.2 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.8.3 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.8.4 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.8.5 Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market (by Application)

4 Company Profiles

• 4.1 Overview
• 4.2 Manufacturers
  • 4.2.1 bioMerieux SA
    • 4.2.1.1 Company Overview
    • 4.2.1.2 Role of bioMerieux SA in the Cell and Gene Therapy Manufacturing QC Market
    • 4.2.1.3 Key Competitors
    • 4.2.1.4 Financials
    • 4.2.1.5 Analyst Perspective
  • 4.2.2 F. Hoffmann-La Roche Ltd
    • 4.2.2.1 Company Overview
    • 4.2.2.2 Role of F. Hoffmann-La Roche Ltd in the Cell and Gene Therapy Manufacturing QC Market
    • 4.2.2.3 Key Competitors
    • 4.2.2.4 Financials
    • 4.2.2.5 Key Insights about the Financial Health of the Company
    • 4.2.2.6 Analyst Perspective
  • 4.2.3 Lonza.
    • 4.2.3.1 Company Overview
    • 4.2.3.2 Role of Lonza. in the Cell and Gene Therapy Manufacturing QC Market
    • 4.2.3.3 Key Competitors
    • 4.2.3.4 Financials
    • 4.2.3.5 Analyst Perspective
  • 4.2.4 Miltenyi Biotec B.V. & Co. KG
    • 4.2.4.1 Company Overview
    • 4.2.4.2 Role of Miltenyi Biotec B.V. & Co. KG in the Cell and Gene Therapy Manufacturing QC Market
    • 4.2.4.3 Key Competitors
    • 4.2.4.4 Analyst Perspective
  • 4.2.5 Sartorius AG
    • 4.2.5.1 Company Overview
    • 4.2.5.2 Role of Sartorius AG in the Cell and Gene Therapy Manufacturing QC Market
    • 4.2.5.3 Key Competitors
    • 4.2.5.4 Financials
    • 4.2.5.5 Analyst Perspective
• 4.3 Service
  • 4.3.1 Eurofins Scientific
    • 4.3.1.1 Company Overview
    • 4.3.1.2 Role of Eurofins Scientific in the Cell and Gene Therapy Manufacturing QC Market
    • 4.3.1.3 Key Competitors
    • 4.3.1.4 Financials
    • 4.3.1.5 Analyst Perspective
  • 4.3.2 Merck KGaA
    • 4.3.2.1 Company Overview
    • 4.3.2.2 Role of Merck KGaA in the Cell and Gene Therapy Manufacturing QC Market
    • 4.3.2.3 Key Competitors
    • 4.3.2.4 Financials
    • 4.3.2.5 Analyst Perspective